D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock.

Several other equities research analysts have also recently commented on CNTX. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. William Blair initiated coverage on shares of Context Therapeutics in a research note on Monday, April 21st. They issued an “outperform” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, JMP Securities initiated coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Context Therapeutics presently has an average rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Price Performance

Shares of CNTX stock opened at $0.87 on Tuesday. Context Therapeutics has a one year low of $0.55 and a one year high of $2.75. The business’s 50 day simple moving average is $0.78 and its 200 day simple moving average is $1.18. The stock has a market capitalization of $77.77 million, a PE ratio of -0.95 and a beta of 2.18.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. As a group, research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently bought and sold shares of the stock. Shay Capital LLC purchased a new position in Context Therapeutics during the 4th quarter worth $52,000. MPM Bioimpact LLC bought a new position in shares of Context Therapeutics during the fourth quarter valued at about $15,441,000. Millennium Management LLC boosted its holdings in Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after purchasing an additional 34,835 shares during the last quarter. Citadel Advisors LLC bought a new stake in Context Therapeutics in the 4th quarter worth about $31,000. Finally, Allostery Investments LP purchased a new stake in Context Therapeutics in the 4th quarter valued at about $998,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.